MedWatch

”Come 2013 we will be fit for fight”

The CEO of Exiqon acknowledges that the company has under-performed in the US. A new sales strategy and new, scientific workers are going to turn it all around.

Foto: Exiqon / PR

For the second quarter running the Danish medtech company Exiqon has presented a record-turnover powered by increasing sales figures in Europe. However, the sale of research products and services in the US has dropped off by 14 % compared with the same period last year. And that development needs to be turned around.

“What is important to us is that our turnover is on the rise. It is still not at the level we want it to be – it needs to grow even more, and it will,” CEO Lars Kongsbak tells medwatch, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 38

Ugen bød på en milliardkontrakt til Bavarian Nordic, mens Novo Nordisk forventer at sende et ugentligt insullin på markedet inden længe. Medicinrobotter skal erstatte manglende medarbejdere i sundhedsvæsenet. Gik du glip af noget?

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier